Trianni has finalized a non-exclusive license agreement with Fred Hutchinson Cancer Research Center (Fred Hutch), a world leader in lifesaving research to prevent, detect and treat cancer, HIV/AIDS and other deadly diseases, allowing access to The Trianni Mouse, a best-in-class monoclonal antibody discovery platform.

“We are pleased to have Fred Hutch as a partner,” stated Dr. David Meininger, Trianni’s chief business officer. “With the Trianni Mouse platform’s distinctive features, most notably a complete human antibody repertoire expressed from chimeric V-gene segments, we anticipate our platform will be a vital instrument in Fred Hutch’s life-saving research.”

Fred Hutch’s Director of Therapeutic Peptide Initiative, Dr. Chris Mehlin, said “One of the historical stumbling blocks for the development of antibodies as therapeutics is that they typically have to be ‘humanized’ so that patients don’t develop an immune response to the antibody. This process can take a long time, and it is not always successful. The ability to generate fully human antibodies right out of the gate greatly accelerates our ability to bring antibodies to the clinic – it is a powerful tool for the development of new therapeutics.”

Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse.